What You Should Know:
- This week, TaeJong Jay Yang, EVP and Head of Health R&D for Samsung outlined the company’s vision health and wellness.
- Samsung’s health and wellness vision is focused on setting new standards for health experiences through our Galaxy Watch series, and across our broader product portfolio.
Pillars of Samsung’s Health & Wellness Vision
Samsung has established three key pillars to help consumers reach their own goals:
1.
Read More
biotricity
Biotricity Awarded FDA 510(k) Clearance for Cardiac Monitoring Device
What You Should Know:
- Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three-lead device for ECG and arrhythmia monitoring that is intended for lower-risk patients.
- Most remote cardiac monitors are passive — they don’t record ECG and other cardiac data in real-time — and lack cross-compatibility
Read More
Biotricity Launches Heart Monitoring App for Samsung’s Galaxy Watch4 Series
What You Should Know:
- Biotricity Inc., a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Biocare Cardiac - a personal, cardiac health application for individuals diagnosed with or at risk for cardiovascular disease. Designed to be used with Samsung's Galaxy Watch4 series, the Biocare Cardiac application continuously collects users' daily activities and provides critical information on
Read More
Biotricity Releases Mobile Cardiac Telemetry Solution
Biotricity today announced the commercial availability of Bioflux, a real-time, high-precision mobile cardiac telemetry solution for customers. The Bioflux system, which received final FDA approval in December, is a complete solution for cardiac monitoring and diagnosis, consisting of the Bioflux device, proprietary software, and a 24/7 monitoring center that merges seamlessly with physicians’ existing platforms and workflows.The Bioflux system is a complete solution for cardiac monitoring and
Read More
Medical Wearables: How Next Generation Devices Will Change Healthcare
Medical patient monitoring devices are poised to disrupt the healthcare industry. According to Markets and Markets, the global market for medical wearable devices is projected to reach $12.1 billion by 2021, with the United States representing the largest market worldwide. With the ability to enhance the healthcare system by aiding in the remote monitoring of patients, wearables provide real-time access to health records and provide quicker diagnosis and treatment of conditions.They are
Read More
Biotricity Awarded FDA 510(k) Clearance for its Biometric Remote Monitoring Device
Biotricity - a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, that details how the Company has received its 510(k) clearance for its Bioflux device with the U.S. Food and Drug Administration (FDA). This latest 510(k) is the final FDA requirement needed for Biotricity to bring to market Bioflux in the U.S.Bioflux consists of a proprietary mobile ECG monitoring device and an ECG viewer software package, that
Read More
Biotricity Awarded Ethics Approval to Validate Mobile Wireless Fetal Monitoring
Biotricity, Inc., a provider of biometric remote monitoring solutions has been awarded ethics approval to conduct a study that will investigate and validate a mobile wireless fetal heart rate variability (HRV) monitor. Conducted at Rockyview General Hospital, the findings of the study will be used to build on the research of Biotricity’s flagship product Bioflux which is currently awaiting final FDA clearance and will be the second major app for the clinical-grade remote patient monitoring
Read More
Biotricity Files for Final FDA 510(k) Clearance for Remote Cardiac Monitoring Wearable
biotricity, a Redwood City, CA-based healthcare technology company has filed for a second and final 510(k) for the hardware portion of its remote cardiac monitoring software and device, Bioflux solution with the U.S. Food and Drug Administration (FDA). The announcement follows a previous milestone where Biotricity received FDA approval for the software portion of its remote cardiac monitoring wearable.This 510(k) is the final regulatory requirement needed for Biotricity to bring its Bioflux
Read More
biotricity Receives FDA 510(k) Clearance for Wearable Biometric Cardiac Monitoring
biotricity, a Redwood City, CA-based healthcare technology company has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a key component of its remote cardiac monitoring software and device, bioflux. Available only by subscription, bioflux will monitor a patient’s heart rhythm and send data in real-time to a 24-hour monitoring lab. If a patient is in cardiac distress, an alert will be sent to the monitoring center, which will in turn contact the patient to offer
Read More
